X

Trial Profile

MERS-CoV Infection tReated With A Combination of Lopinavir /Ritonavir and Interferon Beta-1b: a Multicenter, Placebo-controlled, Double-blind Randomized Trial

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 15 Oct 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Interferon beta-1b (Primary) ; Lopinavir/ritonavir (Primary)
Indications Middle East respiratory syndrome coronavirus
Focus Therapeutic Use
Acronyms MIRACLE

Most Recent Events

07 Oct 2020 Status changed from recruiting to discontinued, according to results published in the New England Journal of Medicine.
07 Oct 2020 Results published in the New England Journal of Medicine
03 Jan 2020 Trial design published in the Trials.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com